4th Circuit Affirms Dismissal of FCA Medicaid Suit Against Allergan

On January 25, 2022, a majority of the Fourth Circuit panel affirmed the dismissal of a relator's False Claims Act complaint against Allergan Sales LLC, alleging Medicaid fraud. In the underlying case, the plaintiffs alleged that Allergan engaged in a fraudulent price reporting scheme under the Medicaid Drug Rebate Statute by failing to aggregate discounts given to separate customers for purposes of reporting the "best price," allegedly costing the government at least $680 million.